Navigation Links
Biopure Announces Date to Meet with UK's Medicines and Healthcare Products Agency
Date:5/2/2008

CAMBRIDGE, Mass., May 2 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced that a meeting with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) is scheduled for May 29, 2008 in the UK.

The purpose of the meeting is to clarify the issues outlined in a letter Biopure received in April 2008 from the United Kingdom's Commission on Human Medicines regarding the company's application for marketing authorization for Hemopure(R). The issues relate to quality, clinical efficacy, safety and the reliability of data monitoring and auditing of clinical trials. The letter stated that the Commission was "reassured" on a number of the questions raised in its initial comment letter, but indicated that both "major" and "other" pharmacological and clinical issues either were not yet resolved by the Company's submission made in November 2007 or were only resolved in part.

As Biopure previously announced on April 11, 2008, the MHRA found the Company's Pennsylvania manufacturing facility to be in general compliance with the principles and guidelines of good manufacturing practices as identified in the Commission Directives.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The company is developing Hemopure for other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biopure Operations Compliant With U.K. Manufacturing Guidelines
2. Biopure Appoints New Independent Auditor
3. Biopure Completes U.K. Regulatory Agency Inspection
4. Biopure Announces 2008 First Quarter Financial Results
5. Biopure Launches Updated Website
6. Biopure Announces Pricing of Equity Offering
7. Biopure Gives Update on Malaysia Joint Venture Discussions
8. Pulmo BioTech Announces Appointment of Chief Financial Officer
9. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
10. Solei Systems, Inc., Announces That the Company Is Now Publicly Traded
11. China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Kerr Corporation, a ... video and additional how-to information about dual arch impressions on ... with Dual Arch Impressions,” the blog entry serves up a ... and houses a step-by-step demonstration by Dr. David Little as ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... ... Earned Value Management can improve control over clinical development costs, payments, and accruals and ... , ... June 11, 2009 -- ClearTrial ( www.cleartrial.com ), a leading provider of clinical trial ...
... STAAR Surgical Company (Nasdaq: STAA ), a ... products, today announced that the FDA has granted 510(k) ... the Affinity(TM) Collamer(R) Three-Piece NTIOL and the Elastimide(TM) Silicone ... a new era of insertion devices for the company ...
... June 11 New data from Phase 3 ... (NYSE: WYE ) investigational pneumococcal vaccine, Prevenar 13* ... provide coverage against the 13 most prevalent serotypes associated with ... children younger than five worldwide. , , ...
Cached Biology Technology:ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6
(Date:7/10/2014)... 10, 2014) Consuming a whole fresh avocado with ... enhanced provitamin A carotenoid (alpha- and beta-carotene) absorption and ... vitamin A, according to new research (1) published ... , Vitamin A is involved in reproductive health ... and vision; and has antioxidant properties. Provitamin A carotenoids, ...
(Date:7/9/2014)... diseases can occur simultaneously in distinct sites in ... effective for one disorder may exacerbate the other. ... which alleviates joint disease but can worsen periodontal ... of The American Journal of Pathology ... anti-arthritic drugs, specifically DTrp8-ɣMSH (DTrp), that acts via ...
(Date:7/9/2014)... one gene for another in a line of living ... reality within this decade. As with any new technology, ... disease-causing genes in humans, for example--as well as questions ... of those concerns to rest: using gene-editing techniques on ... in the cells. The new results were published July ...
Breaking Biology News(10 mins):New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2New class of anti-arthritis drugs effectively treats multiple inflammatory diseases 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3
... Rebekah E. Gee MD MPH FACOG, Assistant Professor, LSU ... and Medicine, has been chosen to receive a Recognition ... Leadership Award from the Association of Maternal & Child ... vision, and contributions to the health of women, children, ...
... The University of Michigan,s first human embryonic stem cell line ... registry, making the cells available for federally-funded research. It is ... University of Michigan to be placed on the registry. ... derived in October 2010 from a cluster of about 30 ...
... cues from their rivals the honeybees to learn where the ... Mary, University of London. Writing in the journal ... Biological and Chemical Sciences explain how they trained a colony ... by a different species, the honeybee ( Apis mellifera ), ...
Cached Biology News:LSUHSC's Gee honored for improving health of women, children and families 2U-M human embryonic stem cell line placed on national registry 2U-M human embryonic stem cell line placed on national registry 3Bumblebees get by with a little help from their honeybee rivals 2
...
...
... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
Biology Products: